Vascular endothelial growth factor suppresses TNFSF15 production in endothelial cells by stimulating miR-31 and miR-20a expression via activation of Akt and Erk signals. 2017

Hui-Ting Deng, and Hai-Lin Liu, and Bei-Bei Zhai, and Kun Zhang, and Guo-Ce Xu, and Xue-Mei Peng, and Qiang-Zhe Zhang, and Lu-Yuan Li
State Key Laboratory of Medicinal Chemical Biology and College of Pharmacy, and Tianjin Key Laboratory of Molecular Drug Research Nankai University China; Collaborative Innovation Center for Biotherapy Nankai University West China Hospital Sichuan University Chengdu China.

Tumor necrosis factor superfamily-15 (TNFSF15; VEGI; TL1A) is a negative modulator of angiogenesis for blood vessel homeostasis and is produced by endothelial cells in a mature vasculature. It is known to be downregulated by vascular endothelial growth factor (VEGF), a major regulator of neovascularization but the mechanism of this interaction is unclear. Here we report that VEGF is able to stimulate the production of two microRNAs, miR-20a and miR-31, which directly target the 3'-UTR of TNFSF15. Additionally, we show that two VEGF-stimulated cell growth signals, Erk and Akt, are responsible for promoting the expression of miR-20a and miR-31. Treatment of human umbilical vein endothelial cells (HUVECs) with Akt inhibitor LY294002 results in diminished miR-20a and miR-31 production, while Erk inhibitor U0126 prevented VEGF-stimulated expression of miR-20a but not that of miR-31. Furthermore, inactivation of either Erk or Akt signals restores TNFSF15 gene expression. In an angiogenesis assay, elevated miR-20a or miR-31 levels in HUVECs leads to enhancement of capillary-like tubule formation in vitro, whereas lowered miR-20a and miR-31 levels results in an inhibition. These findings are consistent with the view that miR-20a and miR-31 mediate VEGF-induced downregulation of TNFSF15. Targeting these microRNA molecules may therefore provide an effective approach to inhibit angiogenesis.

UI MeSH Term Description Entries

Related Publications

Hui-Ting Deng, and Hai-Lin Liu, and Bei-Bei Zhai, and Kun Zhang, and Guo-Ce Xu, and Xue-Mei Peng, and Qiang-Zhe Zhang, and Lu-Yuan Li
October 2016, Oncotarget,
Hui-Ting Deng, and Hai-Lin Liu, and Bei-Bei Zhai, and Kun Zhang, and Guo-Ce Xu, and Xue-Mei Peng, and Qiang-Zhe Zhang, and Lu-Yuan Li
January 2015, BioMed research international,
Hui-Ting Deng, and Hai-Lin Liu, and Bei-Bei Zhai, and Kun Zhang, and Guo-Ce Xu, and Xue-Mei Peng, and Qiang-Zhe Zhang, and Lu-Yuan Li
September 2001, Zhonghua yi xue za zhi,
Hui-Ting Deng, and Hai-Lin Liu, and Bei-Bei Zhai, and Kun Zhang, and Guo-Ce Xu, and Xue-Mei Peng, and Qiang-Zhe Zhang, and Lu-Yuan Li
July 2001, Acta pharmacologica Sinica,
Hui-Ting Deng, and Hai-Lin Liu, and Bei-Bei Zhai, and Kun Zhang, and Guo-Ce Xu, and Xue-Mei Peng, and Qiang-Zhe Zhang, and Lu-Yuan Li
January 2010, Journal of immunology (Baltimore, Md. : 1950),
Hui-Ting Deng, and Hai-Lin Liu, and Bei-Bei Zhai, and Kun Zhang, and Guo-Ce Xu, and Xue-Mei Peng, and Qiang-Zhe Zhang, and Lu-Yuan Li
February 2006, Brain research,
Hui-Ting Deng, and Hai-Lin Liu, and Bei-Bei Zhai, and Kun Zhang, and Guo-Ce Xu, and Xue-Mei Peng, and Qiang-Zhe Zhang, and Lu-Yuan Li
January 2016, PloS one,
Hui-Ting Deng, and Hai-Lin Liu, and Bei-Bei Zhai, and Kun Zhang, and Guo-Ce Xu, and Xue-Mei Peng, and Qiang-Zhe Zhang, and Lu-Yuan Li
June 2006, Molecular cancer research : MCR,
Hui-Ting Deng, and Hai-Lin Liu, and Bei-Bei Zhai, and Kun Zhang, and Guo-Ce Xu, and Xue-Mei Peng, and Qiang-Zhe Zhang, and Lu-Yuan Li
January 2013, PloS one,
Hui-Ting Deng, and Hai-Lin Liu, and Bei-Bei Zhai, and Kun Zhang, and Guo-Ce Xu, and Xue-Mei Peng, and Qiang-Zhe Zhang, and Lu-Yuan Li
October 2009, Cancer science,
Copied contents to your clipboard!